Nancy J Kelley + Associates

Prior to her employment at ARE, Ms. Kelley was Senior Vice President and Managing Director of Life Sciences, worldwide, for Spaulding & Slye Colliers and Colliers International (“Colliers”) where clients included, amongst others, the National Institutes of Health, Johns Hopkins University, the Massachusetts Institute of Technology; Boston University/Boston Medical Center; and Novartis, Pfizer, Genzyme and Perkin Elmer. At the time of Ms. Kelley’s departure, the Colliers Life Sciences Group consisted of more than 110 professionals specializing in structured finance and investment sales, development services, construction, leasing and facility management. The Life Sciences Group had 6 million square feet of life science space under development and managed over 3.5 million square feet of life science facility space.

In 2004, Ms. Kelley was the principal author/editor of Alchemy, a first-of-its-kind Global Life Sciences Real Estate Report intended to help decision-makers from biotechnology and pharmaceutical companies, together with research and health care institutions, speed scientific advances from bench to bedside and beyond. She is also the principal author/editor of Elements, 2007, a follow-on publication that was released by Colliers at BIO 2007. Ms. Kelley has written and spoken extensively on these topics.

Ms. Kelley gained real estate master planning experience in the life sciences arena when she chaired a task force on behalf of the Town of Belmont, Massachusetts that managed the master planning, negotiation and redevelopment of 240 acres of land in Belmont owned by McLean Hospital, Partners Healthcare, and Massachusetts General Hospital. During this three-year process, the McLean Hospital Task Force negotiated an agreement with McLean Hospital that rezoned the property from residential to commercial use and resulted in benefits for the Town of Belmont totaling over $75 million. The Agreement was endorsed by major news editorial Boards, approved overwhelmingly by Town committees and passed by a two-thirds referendum in the Town of Belmont.

As an advisor and founder of growth companies, Ms. Kelley acquired years of experience in growing life science companies from start-up through development into established enterprises. As a former corporate securities junior partner at the Boston law firm of Hale and Dorr (now Wilmer Hale) her practice focused on a range of corporate and securities matters for leading private and publicly traded high technology companies and investment banks in the biotechnology, medical instrumentation, and health care industries. Her specific expertise included: the private placement and public offering of securities, mergers and acquisitions, venture capital investment, research and development agreements, joint ventures, strategic alliances, technology transfer and intellectual property protection.

In addition to her private sector experience, Ms. Kelley has a broad background in the nonprofit, public, and academic sectors.

In 1988-1989, Ms. Kelley was appointed a White House Fellow and served as a Special Assistant to the U.S. Trade Representative in the Executive Office of the President. While studying at Harvard University, she co-founded and led a research and teaching project at the John F. Kennedy School of Government’s Center for Business and Government entitled, “The Community Revitalization Project.” She also founded and taught the first clinical course on social entrepreneurship at Harvard Law School, after having participated in the founding of City Year and other social ventures. In 1982, she was appointed a Truman Scholar from Connecticut.

Ms. Kelley currently serves or has served on Boards for The New York Genome Center, The Jackson Laboratory, Beth Israel Deaconess Medical Center, and the Whitehead Institute, amongst others.